Welcome to our dedicated page for Benitec Biopharm news (Ticker: BNTC), a resource for investors and traders seeking the latest updates and insights on Benitec Biopharm stock.
Benitec Biopharma Inc. develops clinical-stage genetic medicines based on its proprietary Silence and Replace DNA-directed RNA interference platform. The company’s lead program, BB-301, is a silence-and-replace therapeutic in development for dysphagia in patients with Oculopharyngeal Muscular Dystrophy, or OPMD.
Company news primarily covers BB-301 clinical development, including Phase 1b/2a study updates, follow-up data from treated cohorts, safety and clinical-activity observations, and presentations at gene therapy and muscular dystrophy medical meetings. Benitec also issues periodic financial results and operational updates tied to its development-stage biotechnology business.
Benitec Biopharma Inc. (NASDAQ: BNTC) reported a significant decline in total revenues for FY 2020, totaling $102,000 compared to $12.2 million in FY 2019, primarily due to the termination of the Axovant Sciences Agreement. Net loss increased to $8.27 million, or $8.10 per share, compared to a profit of $2.6 million in 2019. The company concluded the fiscal year with $9.8 million in cash. Despite these challenges, Benitec is optimistic about the ongoing development of its BB-301 program for Oculopharyngeal Muscular Dystrophy, having initiated pivotal studies in 2020.
On September 1, 2020, Benitec Biopharma (NASDAQ: BNTC), a biotechnology company focusing on gene therapy, announced that its CEO, Jerel A. Banks, M.D., Ph.D., will present at the H.C. Wainwright 22nd Annual Global Investment Conference. The presentation is scheduled for September 16, 2020, at 11:30 A.M. EDT. It will be available via webcast, with a link provided for registration. Benitec is developing ddRNAi-based therapies for serious conditions like Chronic Hepatitis B and Oculopharyngeal Muscular Dystrophy. For more details, visit Benitec's investor relations site.